Jiang Jiao, Li Hongjuan, Chen Lin, Qiu Xiaoming
Lung Cancer Center, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, 610061, P.R. China.
Department of Thoracic Surgery/Lung Cancer Center, China Hospital, Sichuan University, Chengdu, 610061, P.R. China.
J Cardiothorac Surg. 2024 Dec 30;19(1):685. doi: 10.1186/s13019-024-03311-8.
To clarify the prognostic role of pretreatment albumin-bilirubin (ALBI) grade in lung cancer patients.
The PubMed, EMBASE, Web of Science and CNKI databases were searched up to April 20, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis based on the type of lung cancer [non-small cell lung cancer (NSCLC) vs. small cell lung cancer (SCLC)] and treatment [surgery vs. immune checkpoint inhibitors (ICIs) vs. chemotherapy] was conducted.
Eight studies with 2,057 patients were included. Pooled results indicated that elevated pretreatment ALBI grade was significantly related to poor OS (HR = 2.50, 95% CI: 2.03-3.09, P<0.001), PFS (HR = 1.91, 95% CI: 1.56-2.33, P<0.001) and CSS (HR = 1.90, 95% CI: 1.11-3.11, P = 0.018). Subgroup analysis for OS based on the pathological type and primary treatment manifested similar results.
Pretreatment ALBI grade is associated with prognosis in lung cancer and patients with elevated ALBI grade are more likely to experience worse survival.
阐明治疗前白蛋白-胆红素（ALBI）分级在肺癌患者中的预后作用。
检索截至2024年4月20日的PubMed、EMBASE、Web of Science和CNKI数据库。主要结局包括总生存期（OS）、无进展生存期（PFS）和癌症特异性生存期（CSS）。合并具有95%置信区间（CI）的风险比（HR），并基于肺癌类型[非小细胞肺癌（NSCLC）与小细胞肺癌（SCLC）]和治疗方式[手术与免疫检查点抑制剂（ICI）与化疗]进行亚组分析。
纳入8项研究，共2057例患者。汇总结果表明，治疗前ALBI分级升高与较差的OS（HR = 2.50，95% CI：2.03 - 3.09，P < 0.001）、PFS（HR = 1.91，95% CI：1.56 - 2.33，P < 0.001）和CSS（HR = 1.90，95% CI：1.11 - 3.11，P = 0.018）显著相关。基于病理类型和初始治疗的OS亚组分析显示了相似结果（此处原文有误，应是基于病理类型和初始治疗）。
治疗前ALBI分级与肺癌预后相关，ALBI分级升高的患者生存情况更差（此处原文有误应是生存情况更差）。 （注：原文中部分错误已在括号内修正）
